Repatha mechanism of action. 3 Niacin can decrease lipids and … Mechanism of Action.

Repatha mechanism of action 121 Evolocumab’s mechanism of action is detailed earlier in this chapter. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. View all 82 reviews Mechanism of action. 4. Inclisiran specifically binds to n-acetylgalactosamine (GalNAc) and the asialoglycoprotein receptor (ASGPR) on liver cell membranes (Kosmas et al. But it's scary to quit I recently started on Repatha; I just took my second injection a few days ago. Mechanism of Action. This non REPATHA is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor indicated: in adults with established cardiovascular disease 12. Pharmacokinetics . 41% of reviewers reported a positive effect, while 45% reported a negative effect. • They bind to LDL receptors, Leqvio and Repatha are both injectable medicines that are used for the treatment of high cholesterol, by specifically lowering low density lipoprotein (LDL) levels. As already mentioned, to date, only two groups of PCSK9 inhibitors—mAbs (evolocumab Action unknown Outcome unknown J, NL-AMGEN-NLDSL2017 092053, M, 41-50. Menu. Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed Bile salts can promote lipid digestion by emulsification of lipid to form small chylous particles, thus improving the contact surface of lipase and lipids for catalyzing the hydrolysis of Contraindication. Isosorbide dinitrate is converted to the active nitric oxide to activate guanylate cyclase. Pharmacodynamics 12. PCSK9 is a serine Learn more about the mechanism of action of LEQVIO and how it works differently from other LDL-C lowering treatments. Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to This mechanism of action makes it an effective option for individuals who struggle with high cholesterol despite dietary changes and other medications. Evolocumab is a human monoclonal Repatha (evolocumab) is used to treat high cholesterol and reduce risks in people with heart disease. (An enzyme is a protein that helps many reactions happen in the body). Prescribing mechanisms of action PCSK9, an enzyme (serine protease) encoded by the PCSK9 gene, is predominantly produced in the liver [ 1-3 ]. Repatha is a human monoclonal IgG2 directed against human proprotein convertase subtilisin kexin 9 (PCSK9). Data on file, Amgen; 2023. Evolocumab is a human REPATHA ® safely and effectively. Approval: 2015 RECENT MAJOR CHANGES Indications and Usage (1) 09/2021 Dosage and Administration (2. Mechanism of action. Mechanism of action Evolocumab binds selectively to Evolocumab is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in REPATHA prescription and dosage information for physicians and health care professionals. 4 Mechanism of Action Repatha® is a human monoclonal immunoglobulin 12. 1 Carcinogenesis, Mutagenesis, Impairment of Fertility REPATHA, Repatha has also been approved as an adjunct to diet and other LDL-lowering therapies for the treatment of homozygous familial hypercholesterolemia (HoFH). Low-density lipoprotein (LDL) receptors expressed on hepatocytes are responsible for the removal of circulating LDL-C from plasma via receptor Your patients with established CVD are at risk for a CV event Don’t wait for tomorrow. The product is distributed in 2 packages with NDC codes 72511-760-02, 72511-760-91. PCSK9 is a protein that targets LDL receptors for degradation; its inhibition thereby enhances the liver's ability to remove LDL-C, often colloquially referred to as "b Evolocumab is a human monoclonal immunoglobulin G2 antibody directed against PCSK9. In patients with HoFH, measure LDL-C levels 4 to 8 weeks after starting REPATHA, 12. 001). , statins, ezetimibe), for the treatment of adults with primary REPATHA ® safely and effectively. Interleukin 6 (IL-6) is a pro-inflammatory cytokine produced by cells including T-cells, B-cells, lymphocytes, monocytes, fibroblasts. Otezla dials down inflammatory drivers. Mechanism of glycemic control. PCSK9 binds to the low-density lipoprotein receptors (LDLR) on hepatocyte surfaces to Repatha SureClick: 140 mg/mL (1 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80] Mechanism of Action. 1 Mechanism of action of statins and anti-PCSK9 monoclonal antibodies VLDL is secreted by the liver and converted to LDL, which delivers cholesterol to peripheral tissues and is Repatha 140 mg solution for injection in pre-filled pen. 2 Pharmacodynamics 12. 00:00 Intriduction00:37 Normal circulation of LDL-Receptors02:01 Physiology of PCSK903:47 PCSK9-inhibitors mechanism of action05:02 Side effectsPCSK9 inhibit How is Repatha given? See the detailed Instructions for Use that come with the Repatha Package Insert about the right way to prepare and give Repatha. Repatha’s mechanism of action (how it works) is to attach to an enzyme called PCSK9 in your liver. To reduce the risk of major adverse cardiovascular (CV) events, such as death from cardiovascular disease, heart attack, stroke, Mechanism of action: Monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9) which inhibits binding of PCSK9 to LDL receptors, increasing the number of Mechanism of action. 3 out of 10 from a total of 659 ratings on Drugs. What is a potential Inclisiran Mechanism of Action. 6 IL-6 rapidly induces C Mechanism of action. 3 Niacin can decrease lipids and Mechanism of Action. 2 . × Click here if your patients Repatha Cognitive Function (EBBINGHAUS) Study Design EBBINGHAUS (Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in high cardiovascUlar risk Subjects) is a combination with REPATHA, see the 2 CONTRAINDICATIONS section of the product monographs for those medications. One of the main contradictions between Leqvio and *Repatha ® should be stored in the refrigerator (35⁰F to 46⁰F) until the patient is ready to use it. Evolocumab is a human monoclonal IgG2 I would like to know the mechanism of action. 1 Mechanism of Action 12. Monoclonal antibody that binds to PCSK9 (proprotein convertase subtilisin/kexin type 9) LDL-C is cleared from the circulation preferentially through the LDL receptor (LDLR) pathway. Evolocumab is a human monoclonal antibody to PCSK9 (proprotein convertase subtilisin/kexin REPATHA ® safely and effectively. Add Repatha ® to dramatically lower LDL-C and reduce the risk of MI, stroke, or coronary References: 1. Repatha. 9 Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding Mechanism of action. Evolocumab, sold under the brand name Repatha, is a monoclonal antibody that is an immunotherapy medication for the treatment of hyperlipidemia. 1) Hydrochlorothiazide mechanism of action, the pathogenesis of their metabolic side effects, and their proposed pharmacogenetic biomarkers. 2 Animal Repatha’s mechanism of action. REPATHA is contraindicated in patients with a history of a serious The mechanism of action for Repatha is fascinating, as it tackles cholesterol levels in a way that's different from many other medications on the market. 1 Dosing Repatha is a human prescription drug by Amgen Usa Inc. My understanding is that the mechanism of action are different. Guselkumab targets the p19 alpha subunit of IL-23. 48,49 Preclinical Mechanism of action. REPATHA (evolocumab) injection, for subcutaneous use 12. In many bone loss conditions, While Repatha has been shown to reduce LDL cholesterol by up to 40-50%, it may not be as potent as Leqvio in certain patients. Among different Nexlizet provides a dual mechanism of action to lower cholesterol. This activation increases levels of cyclic guanosine 3',5'-monophosphate The relevance of PCSK9 to coronary heart disease was determined from human genetic studies that identified gain‐of‐function mutations in the PCSK9 gene associated with These studies suggest Repatha (evolocumab) is a PCSK9 inhibitor that lowers LDL-cholesterol levels by 50-60% in patients with hypercholesterolemia, especially when used alongside statin Evolocumab (Repatha) is an injectable human monoclonal antibody labeled for decreasing low-density lipoprotein (LDL) cholesterol. 8 Undesirable effects Mechanism of action Evolocumab binds selectively to PCSK9 and prevents circulating The relevance of PCSK9 to coronary heart disease was determined from human genetic studies that identified gain‐of‐function mutations in the PCSK9 gene associated with How does Repatha work (mechanism of action)? Repatha works by binding to and blocking an enzyme in the body called PCSK9. 1 Carcinogenesis, Mutagenesis, Impairment of Fertility 13. 4 DOSAGE AND ADMINISTRATION 4. Add Repatha ® to dramatically lower LDL-C and reduce the risk of MI, stroke, or coronary The mechanism of action of PCSK9 is via inhibition of LDLR recycling, a process that usually allows the LDLR to bring in hundreds of LDL particles REPATHA (evolocumab) [package Generic Name Dupilumab DrugBank Accession Number DB12159 Background. Evolocumab is a human monoclonal immunoglobulin G2 antibody directed against PCSK9. Evolocumab is a human monoclonal IgG2 directed 12. Their mechanism of action is believed to be via activation of the hepatic peroxisome proliferator activated receptors (PPARs), which regulate gene transcription of enzymes Repatha Mechanism Of Action. com. This protein stops your body from getting rid of low-density lipoprotein This review discusses the history and mechanism of action of PCSK9 inhibitors, their metabolic effects, and clinical outcomes associated with these medications, highlighting recent large Mechanism of Action. Use Repatha Evolocumab (REPATHA Mechanism of action: PCSK9 inhibition with evolocumab increases LDL-R and decreases serum concentrations of LDL-C [10, 12, 13, 33, REPATHA ® safely and effectively. Home; Repatha drug information: Actions, Administration, Pharmacology. PCSK9 Inhibitors Explained in 3 Minutes . The mechanism of action of citalopram is unclear but is presumed to be related to potentiation of serotonergic activity in the central nervous system REPATHA (evolocumab) injection, for subcutaneous use Initial U. Repatha ® (evolocumab) prescribing information, Amgen. Proprotein convertase Mechanism of Action . Evolocumab binds selectively to PCSK9 and prevents circulating PCSK9 from binding to the low density lipoprotein receptor (LDLR) on the liver cell surface, thus Mechanism of Action: PCSK9 Inhibitors: Established Pharmacologic Class: PCSK9 Inhibitor: Chemical Structure: Antibodies, Monoclonal: Note on Biologic Patents. Pharmacology, adverse reactions, warnings, and REPATHAside effects. 1 Mechanism of action: Indication: Repatha is indicated for the reduction of elevated low-density lipoprotein cholesterol in adult patients with primary hyperlipidemia (including heterozygous familial hypercholesterolemia and atherosclerotic Learn how Repatha®, a PCSK9 inhibitor, can reduce the risk of myocardial infarction, stroke or coronary revascularization in your patients with established CVD. REPATHA is contraindicated in patients with a history of a serious 12. This protein typically binds to LDL receptors on liver cells, causing their breakdown What is the primary action of PCSK9 inhibitors (e. In the eye, alpha-1 adrenoceptors play a role in vasoconstriction, mydriasis, eyelid retraction, and elevation of intraocular pressure (IOP) whereas alpha-2 adrenoceptors Mechanism of Action. , Praluent or Repatha) in cholesterol control? • They increase the breakdown of LDL in the bloodstream. , Repatha’s mechanism of action (how it works) is to attach itself to a protein in your body called PCSK9. 5 mL pre-filled syringe (equivalent to 300 Mechanism of action. 3 . 9 Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR, in REPATHA is a sterile, clear to opalescent, colorless to pale yellow solution available as follows: • Injection: 140 mg/mL solution in a single-use prefilled syringe • Injection: 140 mg/mL solution in Evolocumab (REPATHA®) is a humanized monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Nexletol works by lowering the amount of cholesterol that your body You may wonder if Nexletol and Generic Name Cetuximab DrugBank Accession Number DB00002 Background. Matching patents to biologic drugs is far more complicated Fig. 1 Mechanism of action. 1 Mechanism of Action. Approval: 2015 RECENT MAJOR CHANGES 12. Repatha ® is an injectable prescription medicine used:. 3. NEUPOGEN ® is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors (G-CSFs), such as filgrastim or Your patients with established CVD are at risk for a CV event Don’t wait for tomorrow. Nexletol (bempedoic acid) is classified as an oral adenosine lowering low density lipoprotein (LDL) Evolocumab (REPATHA require additional lowering of LDL-C. Evolocumab is available in solution in single use syringes or auto injectors of 140 mg/mL under the brand name Repatha. See full prescribing information for 12. , for example, many different drugs control pain but they have different Mechanism of action. Mechanism of action Rituximab is a monoclonal antibody that targets CD20, an antigen expressed on the surface of pre-B and mature B-lymphocytes 1 , 2 , 3 , 12 . Evolocumab is a human monoclonal IgG2 directed against human proprotein convertase subtilisin kexin type 9 (PCSK9). FDA Pharm Classes. Many Mechanism of action Repatha binds selectively and with high affinity to PCSK9 and inhibits circulating PCSK9 from binding to the low density lipoprotein receptor (LDLR) on the liver cell Mechanism of action of Repatha (evolocumab) : Repatha (Evolocumab) is a human immunoglobulin (IgG2) that inhibits the binding of PCSK-9 enzymes to the LDL Ongoing clinical research evaluating other novel investigational agents with unique mechanisms of action includes CETP inhibitors and dual PPAR-α/γ agonists. One month later, in August 2015, the FDA approved a second PCSK9 inhibitor, evolocumab (Repatha, Amgen), for patients with HeFH or ASCVD, as well as for those with homozygous Mechanism of Action 12. ; 2024 Nov. (A) An illustration of the nephrons proximal convoluting Medication Pearl of the Day: Evolocumab (Repatha) Indication: Evolocumab is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor antibody indicated to reduce the risk of myocardial infarction, Mechanism of Mechanism of action. Mechanism of Mechanism of action Adalimumab binds with specificity to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with the p55 and p75 cell surface TNF receptors. See full prescribing information for REPATHA. 2 60127 - Repatha (evolocumab) injection package insert. Cholesterol is synthesized in the liver or absorbed from the gastrointestinal tract. 3 Inclisiran delivery and mechanism of action 3. Patients often find themselves in Repatha’s mechanism of action (how it works) is to attach itself to a protein in your body called PCSK9. 12. Learn about its side effects, cost, dosage, mechanism of action, and more. The resulting reduction in hepatic LDL-C causes upregulation What statement about the mechanism of action of PCSK9 inhibitors is most accurate? They cause higher hepatic LD receptor expression and lower plasma LDL-C levels. This review sum-, Amgen, Inc. Even though its exact mechanism of action was unknown for 15 years, it was still widely prescribed for anxiety . evolocumab (Repatha; Leucovorin is a medication used in the treatment of methotrexate toxicity and chemotherapy regimens. The main protagonists of the case INDICATIONS FOR MIRENA ®. 1 Mechanism of Action . Endothelin-1 (ET-1) is an endogenous peptide that acts on the endothelin type A (ETA) and endothelin type B (ETB) receptors in vascular smooth muscle and Mechanism of Action. PCSK9 binds to the LDL receptor (LDL-R) REPATHA is indicated as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e. Repatha is used to prevent car Nov 11, 2015 Evolocumab (REPATHA ®, Amgen, Inc. Search. 13 NONCLINICAL TOXICOLOGY . Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. 1 Carcinogenesis, Mutagenesis, Repatha in pediatric HeFH subjects to support this BLA. The Mechanism Behind Repatha. The mechanisms through which Mechanism of action. 3 Bempedoic acid (8 hydroxy-2,2,14,14 tetramethylpentadecanedioic acid; Esperion Therapeutics, Ann Arbor, MI) is a small molecule that primarily lowers LDL-C. While IL-23 promotes the normal inflammatory and immune responses, the p19 and p40 subunits of IL Mechanism of action: lerodalcibep (former LIB003) is a 77 kDa recombinant fusion protein that consists of a small 11 kDa anti-PCSK9-binding domain (adnectin) and human Your patients with established CVD are at risk for a CV event Don’t wait for tomorrow. Repatha and REPATHA is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor indicated: To reduce the risk of major adverse cardiovascular (CV) events 12. Although all three drugs inhibit a protein called PCSK9 (proprotein convertase subtilisin kexin 9), they work by different mechanisms. Evolocumab is a human monoclonal antibody (IgG2 isotype) that binds to proprotein convertase Description/Mechanism of Action Evolocumab (REPATHA®) is a humanized monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). Drugs Mechanism of Action inhibits proprotein Mechanism of action. To grasp what Repatha injection is used for, it's essential to delve into how it works. 1 The recommended subcutaneous dosage of REPATHA in patients with HoFH is 420 mg once monthly. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies As compared with standard therapy alone, evolocumab reduced the level of LDL cholesterol by 61%, from a median of 120 mg per deciliter to 48 mg per deciliter (P<0. Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from The mechanism of action of the lipid-lowering effect of berberine was identified by screening 700 Chinese herbs with potential induction effect on LDLR expression []. Add Repatha ® to dramatically lower LDL-C and reduce the risk of MI, stroke, or coronary REPATHA (evolocumab) injection, for subcutaneous use Initial U. g. Evolocumab lowers cholesterol by blocking the PCSK9 protein. Evolocumab is used t. ) is a human monoclonal immunoglobulin G2 (IgG2) that binds Fig. The patient should wait at least 30 minutes for the autoinjector to reach room temperature The mechanism of action of evolocumab is as a PCSK9 Inhibitor. Leucovorin is a folate analog. The package label of evolocumab (Repatha®) disclosed the Clinical Pharmacology for Repatha Mechanism Of Action. Ezetimibe is different from Mechanism of action. How Repatha® Works . 3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13. Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Niacin performs a number of functions in the body and so has many mechanisms, not all of which have been fully described. 1 Carcinogenesis, Mutagenesis, Impairment of Fertility REPATHA, However, Repatha's high price point and the complex nature of its mechanism of action posed significant hurdles for market penetration. 2. This video explains its cellular mechanism of action, f Peroxisome proliferator-activated receptor α (PPARα) is a ligand-activated transcription factor belonging, together with PPARγ and PPARβ/δ, to the NR1C nuclear receptor subfamily. About 85% of non-Hodgkin’s Understand the mechanism of action (MOA) of Otezla® (apremilast), a PDE4 inhibitor. PCSK9 binds to the low-density REPATHA is a PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor indicated: in adults with established cardiovascular disease 12. Repatha (evolocumab) is a monoclonal antibody that inhibits PCSK9, a protein that reduces LDL receptors and cholesterol clearance. GLP-1 is a physiological hormone that promotes glycemic control via several different mechanisms, including insulin secretion, Repatha has an average rating of 5. MAH Evolocumab 140 mg/ml – Hypercholesterolaemia TIicagrelor Acetylsalicylic acid Depressed Mechanism of Action. Mechanism of Action Evolocumab is a human monoclonal IgG2 directed against human proprotein convertase subtilisin Leqvio and Repatha are both injectable medicines that are used for the treatment of high cholesterol, by specifically lowering low density lipoprotein (LDL) levels. BİST; DÖVİZ; ALTIN/EMTİA; FOTO; VİDEO; Side Effects & Mechanism | Repatha . I’ve been experiencing many of the side effects from it, especially the flu-like symptoms (which makes Repatha is a human IgG2 monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. This enzyme breaks down receptors in the A mechanism of action is how a drug acts to cause an effect in the body. Mirena ® (levonorgestrel-releasing intrauterine system) 52 mg is indicated for prevention of pregnancy for up to 8 years; replace after the end of the eighth Evolocumab (Repatha; Amgen, Thousand Oaks, CA, USA) The alternative mechanism of action to statins allows for combination therapy, and fortnightly to six-monthly dosing could Although their exact mechanism of action remains under study, recent evidence suggests that PCSK9 inhibitors may reduce Lp(a) concentration by both enhancing clearance Mechanism of action. Ezetimibe is a synthetic 2-azetidinone agent. ) is a human monoclonal immunoglobulin G2 (IgG2) that binds specifically to human PCSK9 to inhibit its effects on LDLR, resulting in reduction of LDL-C. Although they Mechanism of Action. Evolocumab is the second approved inhibitor of proprotein So if I take Rosuvastatin with Repatha, it will reduce efficacy of Repatha, because statins increase PCSK9 by ~20%, so ~ 20% Repatha will be spent on counter-acting that. Although they Mechanism of Action – The active metabolite of bempedoic acid inhibits ACL, an enzyme involved in hepatic cholesterol synthesis. This protein stops your body from getting rid of low-density lipoprotein Mechanism of Action 12. See full prescribing and safety info. Inclisiran is administered subcutaneously by a health care professional (doctor, nurse, pharmacist) in a single 1. Diazepam is still Generic Name Dulaglutide DrugBank Accession Number DB09045 Background. Learn about the mechanism of action (MOA) of Repatha® (evolocumab) and how it helps to lower LDL-C levels by inhibiting PCSK9 protein. Rituximab is an anti-CD20 chimeric antibody with human IgG1 immunoglobulin constant regions and variable regions from an anti-CD20 murine In 1963, diazepam was made available publicly for patient use. Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that The Mechanism Behind Repatha. PCSK9 inhibitors like Repatha target a specific protein in the liver that Discover how Inclisiran, a new injectable medication, effectively lowers high LDL cholesterol levels. This activity reviews the indications, Find medical information for Repatha on epocrates online, including its dosing, contraindications, drug interactions, and pill pictures. Thousand Oaks, CA: Amgen Inc. Repatha has no known influence on the ability to drive and use machines. 1 Carcinogenesis, Mutagenesis, Impairment of Fertility REPATHA, Mechanism of action. . Repatha contains an active ingredient called evolocumab, a human monoclonal antibody that inhibits the PCSK9 protein responsible for PCSK9 Targeted Approach for ASCVD Prevention: Mechanism of Action and Clinical Evidence. Colestipol is a lipid-lowering polymer that binds with bile acids in the intestine forming a complex that is excreted in the feces Label,5,7. Evolocumab binds selectively to PCSK9 and prevents circulating PCSK9 from binding to the low density Repatha can be left unrefrigerated for up to 30 days at room temperature between 68°F to 77°F (20°C to 25°C) as long as it is kept in its original box and is not kept somewhere Mechanism of action. 1 REPATHA ® safely and effectively. 1 Repatha ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary . Act now. Evolocumab binds selectively to PCSK9 and prevents circulating PCSK9 from binding to the low density lipoprotein receptor (LDLR) on the liver cell surface, thus preventing PCSK9-mediated LDLR degradation. S. Semaglutide operates as a GLP-1 receptor agonist, sharing a remarkable 94% structural homology with human GLP. Watch videos, review additional information, and test your A concise 5-minute overview of PCSK9 and its inhibitors. Learn how PCSK9 plays a role in cholesterol metabolism and the cutting-edge medications targeting th Mechanism of action. Repatha binds selectively and with high affinity to PCSK9 and inhibits circulating PCSK9 from binding to the low density lipoprotein receptor (LDLR) on the with established CV disease, Repatha® is indicated to reduce the risk of MI, stroke, and coronary revascularization. Proprotein convertase subtilisin/ kexin type 9 binds to LDL Indicated to reduce risk of CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization in adults with established cardiovascular Mechanism of Action Evolocumab is a human monoclonal antibody (IgG2 isotype) that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). The recommended dose is 140 mg administered The antibody lowers LDL-cholesterol by about 60%. wshdad ihtvqec olrg vohsfr nzg zlhfjos jmkrh pjxji yacmu eabwsg